Long-acting HIV treatment has changed the way some people manage HIV by reducing the need for daily oral medication. One of the best-known long-acting treatments is CABENUVA, an injectable combination of cabotegravir and rilpivirine. CABENUVA is a complete prescription regimen for HIV-1 treatment in adults and adolescents aged 12 years and older who weigh at least 35 kg. In the United States, it is approved as a replacement for an existing antiretroviral regimen in people who are virologically suppressed and meet specific treatment requirements.
CABENUVA combines two antiretroviral medicines:
Both medicines are formulated as extended-release injections. Instead of taking HIV medication every day, CABENUVA is administered by a healthcare professional as two intramuscular injections.
Depending on the prescribed schedule, injections are given once a month or once every two months.
The goal is to maintain effective drug levels between treatment appointments and suppress HIV replication.
CABENUVA is not intended for every person newly diagnosed with HIV.
The FDA indication includes people who:
A healthcare professional evaluates these factors before switching treatment.
Traditional antiretroviral treatment requires medication to be taken regularly, often every day.
Long-acting treatment uses extended-release formulations that slowly release medication into the body.
With CABENUVA, cabotegravir and rilpivirine remain in the body between injections, helping maintain antiviral activity without requiring daily CABENUVA tablets.
This approach can reduce the number of days spent taking oral HIV medication and may make treatment easier for some people.
CABENUVA is administered by a healthcare professional.
Each treatment appointment involves two injections, one containing cabotegravir and the other containing rilpivirine. The injections are given into the muscles of the buttocks.
The treatment can follow either a monthly or every-two-month schedule, depending on the prescribed regimen.
For the every-two-month schedule, the initial injections are given one month apart for the first two months before moving to the every-two-month schedule.
An oral lead-in is not necessarily required for everyone.
The prescribing information states that oral lead-in dosing may be considered before injections to assess tolerability.
When used, the oral lead-in generally involves cabotegravir and rilpivirine tablets for approximately one month.
The healthcare professional determines whether an oral lead-in is appropriate.
Daily medication can be effective, but remembering medication every day can sometimes be difficult.
Long-acting treatment may reduce some of the challenges associated with daily dosing.
Potential advantages can include:
However, injections require regular appointments, so long-acting treatment does not eliminate the need for adherence.
Regular appointments are an essential part of CABENUVA treatment.
The medication remains in the body for an extended period, but missing injections can cause drug levels to decline.
The FDA warns that missed doses can increase the risk of loss of virologic response and development of resistance.
If an injection will be missed by more than seven days, the manufacturer recommends contacting the healthcare provider promptly to discuss treatment arrangements.
CABENUVA has a long pharmacologic "tail," meaning small amounts of cabotegravir and rilpivirine can remain in the body for a prolonged period after injections stop.
The FDA prescribing information states that residual concentrations may remain for 12 months or longer after the last injection.
This is important because stopping treatment without another effective HIV regimen can create a period in which drug concentrations are too low to fully suppress HIV.
A healthcare professional should therefore be contacted promptly if CABENUVA is discontinued so that an appropriate alternative HIV treatment can be arranged.
The primary objective of HIV treatment is to suppress HIV replication.
When treatment successfully lowers HIV RNA to an undetectable level, the immune system can be protected from ongoing HIV replication.
CABENUVA has been studied as a treatment for maintaining viral suppression in people who are already virologically suppressed. The FDA indication specifically requires viral suppression before switching from a stable antiretroviral regimen.
CABENUVA treats HIV but does not eliminate HIV from the body.
It is designed to suppress HIV replication while treatment continues.
People receiving CABENUVA still need ongoing medical care, viral-load monitoring, and adherence to the injection schedule.
As with other medications, CABENUVA can cause side effects.
Injection-site reactions are among the most common concerns and may include:
Other adverse reactions can occur.
The FDA prescribing information also includes warnings concerning hypersensitivity reactions, post-injection reactions, liver-related problems, depressive disorders, drug interactions, and risks associated with the long-acting properties of the medicines.
Because CABENUVA is injected into muscle tissue, injection-site reactions can occur.
Symptoms may include soreness or discomfort around the injection area.
The duration and severity can vary.
Healthcare professionals can provide guidance about managing injection-site reactions and determining whether symptoms require medical evaluation.
CABENUVA can interact with certain medications.
The FDA lists several medicines that should not be taken with CABENUVA, including certain anticonvulsants, rifamycin antibiotics, systemic dexamethasone beyond a single-dose treatment, and St. John's wort.
A complete medication list should be reviewed with the healthcare provider and pharmacist before treatment begins.
This includes:
New medications should also be discussed with the healthcare team.
Liver-related adverse effects have been reported with CABENUVA.
People with existing liver conditions should discuss their medical history with the healthcare professional before starting treatment.
The manufacturer specifically advises discussing previous liver problems, including hepatitis B or hepatitis C infection.
Kidney health can also be relevant when evaluating HIV treatment.
People with kidney problems should tell the healthcare provider about their condition before receiving CABENUVA.
Treatment selection should take into account the full medical history and other medications.
Pregnancy requires individualized medical consideration.
The manufacturer states that it is not known whether CABENUVA can harm an unborn baby and advises discussing pregnancy or plans to become pregnant with a healthcare professional.
CABENUVA can remain in the body for 12 months or longer after the last injection, making treatment planning particularly important when pregnancy is being considered.
The manufacturer also states that CABENUVA may pass into breast milk. Breastfeeding decisions should therefore be discussed with a healthcare professional.
| Feature | CABENUVA | Daily Oral HIV Treatment |
|---|---|---|
| Administration | Two injections | Oral medication |
| Frequency | Monthly or every 2 months | Usually daily |
| Healthcare visit | Required for injections | Usually not required for each dose |
| Daily pill burden | Reduced | Continues |
| Appointment adherence | Very important | Medication adherence is very important |
| Long drug persistence | Yes | Depends on medication |
| Treatment selection | Requires specific eligibility | Many regimen choices |
Neither approach is automatically better for everyone.
The appropriate treatment depends on viral suppression, resistance history, medical conditions, medication interactions, lifestyle, access, and personal preferences.
Long-acting treatment changes the form of adherence rather than eliminating it.
With daily medication, adherence means taking prescribed doses consistently.
With CABENUVA, adherence includes attending scheduled injection appointments.
The manufacturer emphasizes maintaining the planned treatment schedule because missed injections can increase the risk of loss of viral suppression and resistance.